Twist Bioscience CORP Form 4 insider transactions

Patrick John Finn, COO of Twist Bioscience, reports the acquisition of shares through performance stock unit (PSU) vesting and subsequent sale of shares to cover tax obligations.

Adam Laponis, CFO of Twist Bioscience, reports the acquisition of 20,000 shares of common stock on November 4, 2024, as a result of performance stock units meeting their target criteria.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reports acquisition of 8,500 shares and sale of 156 shares to cover tax obligations.

Patrick John Finn, COO of Twist Bioscience, sold 2,261 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Adam Laponis, CFO of Twist Bioscience, sold 856 shares of common stock on October 9, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 3,310 shares of common stock on October 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

CEO Emily Leproust sold shares of Twist Bioscience to cover tax withholding obligations related to vesting Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 6,865 shares of common stock on October 2, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 234 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 297 shares of common stock on September 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

CEO of Twist Bioscience, Emily Leproust, sold 1,730 shares of common stock on September 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 275 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, reports selling 912 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold 240 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold 2,340 shares of common stock on September 6, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reports the sale of 813 shares of common stock on August 23, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 709 shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Patrick John Finn, COO of Twist Bioscience, sold 2,885 shares of common stock on August 5, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Twist Bioscience CEO Emily Leproust sold 5,139 shares of common stock on August 5, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,137 shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 168 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 2,207 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Adam Laponis, CFO of Twist Bioscience, sold 842 shares of common stock on July 9, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 126 shares of common stock on July 2, 2024, at a price of $48.002 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold 1,114 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 322 shares of common stock on July 2, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, COO of Twist Bioscience, sold 476 shares of common stock on July 2, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Emily Leproust, CEO of Twist Bioscience, sold 1,732 shares of common stock on June 20, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.